San Diego, CA – Sept. 20, 2016 – Medical Marijuana, Inc. (OTC: MJNA) announced today that it was the focus of a Mexico Forbes article that discusses the company’s pioneering role in expanding access to medical cannabinoid products to people across Latin America, including bringing the first legal cannabis products to Mexico, Brazil and Paraguay.
The Sept. 19 Mexico Forbes article titled, “Cotiza en los mercados y quiere vender medicina de marihuana en México,” describes how Medical Marijuana, Inc. has been instrumental in the acceptance and legalization of medical marijuana products across Latin America. The article also discusses the market potential for cannabis in the region, including a potential $2 billion opportunity in revenue for Medical Marijuana Inc. in Mexico alone, according to the Company’s Chief Executive Officer Dr. Stuart Titus.
“We are always excited when a major news outlet tells the story of the positive effects of medical cannabinoid products,” said Dr. Titus. “News stories like these bring us one step closer to helping all those who suffer with chronic conditions like epilepsy. For instance, there are currently no effective medical treatments to address seizure disorders in patients who suffer with the refractory form of epilepsy, a patient group that represents a growing portion of the overall epilepsy patient population.”
Dr. Titus added: “We’re seeing a real shift in the way the cannabis plant is being viewed across the globe, including the extracts from the less controversial non-psychoactive hemp plant. Latin America is certainly progressively leading the way in allowing certain cannabis/hemp/CBD products via doctor prescription. We believe hemp CBD will show confirmed medical benefit with future research initiatives; and that hemp will provide future GDP-boosting economic benefits once this region realizes the potential for overall sustainable and renewable industrial application.”
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]